Sugi Predict

Sugi Predict / Targets / TNNI3K

TNNI3K

Serine/threonine-protein kinase TNNI3K · Q59H18 · TNNI3K on Sugi Atlas →

17,873 patent compounds predicted against TNNI3K, 11,983 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL309668 SCHEMBL309668 0.61 20/20
SCHEMBL625579 SCHEMBL625579 0.59 13/20
SCHEMBL691634 SCHEMBL691634 0.59 12/20
SCHEMBL374904 SCHEMBL374904 0.57 12/20
SCHEMBL393893 SCHEMBL393893 0.49 11/20
SCHEMBL374274 SCHEMBL374274 0.53 10/20
SCHEMBL374315 SCHEMBL374315 0.51 9/20
SCHEMBL374155 SCHEMBL374155 0.46 9/20
SCHEMBL626064 SCHEMBL626064 0.41 9/20
SCHEMBL374332 SCHEMBL374332 0.57 8/20
SCHEMBL374148 SCHEMBL374148 0.67 7/20
SCHEMBL270501 SCHEMBL270501 0.53 7/20
SCHEMBL691545 SCHEMBL691545 0.51 7/20
SCHEMBL625074 SCHEMBL625074 0.45 6/20
SCHEMBL573353 SCHEMBL573353 0.62 5/20
SCHEMBL759229 SCHEMBL759229 0.56 5/20
SCHEMBL415712 SCHEMBL415712 0.50 5/20
SCHEMBL127931 SCHEMBL127931 0.46 5/20
SCHEMBL625061 SCHEMBL625061 0.42 5/20
SCHEMBL690354 SCHEMBL690354 0.40 5/20

Clinical trials — most relevant to TNNI3K by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors PHASE2RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... PHASE2COMPLETED
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations PHASE2COMPLETED
Phase I Study of AT13148, a Novel AGC Kinase Inhibitor PHASE1COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib nanCOMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore nanCOMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a TNNI3K binder may also engage these)

ProteinNameSimilarity
Q7TQP6 — 1.000 Q7TQP6 →
Q5GIG6 — 1.000 Q5GIG6 →
Q5RF15 — 0.990 Q5RF15 →
PRKD1 Serine/threonine-protein kinase D1 0.969 landscape →
Q03351 — 0.967 Q03351 →
NTRK2 BDNF/NT-3 growth factors receptor 0.967 landscape →
Q9ESL4 — 0.964 Q9ESL4 →
Q01887 — 0.964 Q01887 →
NTRK3 NT-3 growth factor receptor 0.963 landscape →
P97570 — 0.962 P97570 →
P97819 — 0.962 P97819 →
MAP3K20 Mitogen-activated protein kinase kinase kinase 20 0.962 landscape →
P00535 — 0.961 P00535 →
Q9WTQ1 — 0.961 Q9WTQ1 →
P15209 — 0.961 P15209 →
Q63604 — 0.961 Q63604 →
Q8K1Y2 — 0.961 Q8K1Y2 →
Q62101 — 0.960 Q62101 →
A0A3L7I2I8 — 0.960 A0A3L7I2I8 →
Q5F361 — 0.960 Q5F361 →
Q91044 — 0.960 Q91044 →
Q90999 — 0.960 Q90999 →
Q5XIS9 — 0.960 Q5XIS9 →
P38438 — 0.960 P38438 →
Q91604 — 0.959 Q91604 →
P11273 — 0.959 P11273 →
P34925 — 0.959 P34925 →
E1C1R4 — 0.958 E1C1R4 →
Q3UGM2 — 0.958 Q3UGM2 →
NEK10 Serine/threonine-protein kinase Nek10 0.958 landscape →